Accurate detection and quantitation of heteroplasmic mitochondrial point mutations by pyrosequencing
Accurate detection and quantitation of heteroplasmic mitochondrial point mutations by pyrosequencing
Disease-causing mutations in mitochondrial DNA (mtDNA) are typically heteroplasmic and therefore interpretation of genetic tests for mitochondrial disorders can be problematic. Detection of low level heteroplasmy is technically demanding and it is often difficult to discriminate between the absence of a mutation or the failure of a technique to detect the mutation in a particular tissue. The reliable measurement of heteroplasmy in different tissues may help identify individuals who are at risk of developing specific complications and allow improved prognostic advice for patients and family members. We have evaluated Pyrosequencing technology for the detection and estimation of heteroplasmy for six mitochondrial point mutations associated with the following diseases: Leber's hereditary optical neuropathy (LHON), G3460A, G11778A, and T14484C; mitochondrial encephalopathy with lactic acidosis and stroke-like episodes (MELAS), A3243G; myoclonus epilepsy with ragged red fibers (MERRF), A8344G, and neurogenic muscle weakness, ataxia, and retinitis pigmentosa (NARP)/Leighs: T8993G/C. Results obtained from the Pyrosequencing assays for 50 patients with presumptive mitochondrial disease were compared to those obtained using the commonly used diagnostic technique of polymerase chain reaction (PCR) and restriction enzyme digestion. The Pyrosequencing assays provided accurate genotyping and quantitative determination of mutational load with a sensitivity and specificity of 100%. The MELAS A3243G mutation was detected reliably at a level of 1% heteroplasmy. We conclude that Pyrosequencing is a rapid and robust method for detecting heteroplasmic mitochondrial point mutations.
190-199
White, Helen E.
2181c0b9-fc3b-407e-95eb-3510524603e5
Durston, Victoria J.
7336d597-984a-4ad4-8be4-886b22705061
Seller, Anneke
65633984-704d-40b1-aa56-03a4d717fccc
Fratter, Carl
1b6ff36c-09e1-471c-a9c7-90f4bfdba953
Harvey, John F.
b27b83e2-c681-4a87-9ce9-7686fc1bba36
Cross, Nicholas C.P.
f87650da-b908-4a34-b31b-d62c5f186fe4
2005
White, Helen E.
2181c0b9-fc3b-407e-95eb-3510524603e5
Durston, Victoria J.
7336d597-984a-4ad4-8be4-886b22705061
Seller, Anneke
65633984-704d-40b1-aa56-03a4d717fccc
Fratter, Carl
1b6ff36c-09e1-471c-a9c7-90f4bfdba953
Harvey, John F.
b27b83e2-c681-4a87-9ce9-7686fc1bba36
Cross, Nicholas C.P.
f87650da-b908-4a34-b31b-d62c5f186fe4
White, Helen E., Durston, Victoria J., Seller, Anneke, Fratter, Carl, Harvey, John F. and Cross, Nicholas C.P.
(2005)
Accurate detection and quantitation of heteroplasmic mitochondrial point mutations by pyrosequencing.
Genetic Testing, 9 (3), .
(doi:10.1089/gte.2005.9.190).
Abstract
Disease-causing mutations in mitochondrial DNA (mtDNA) are typically heteroplasmic and therefore interpretation of genetic tests for mitochondrial disorders can be problematic. Detection of low level heteroplasmy is technically demanding and it is often difficult to discriminate between the absence of a mutation or the failure of a technique to detect the mutation in a particular tissue. The reliable measurement of heteroplasmy in different tissues may help identify individuals who are at risk of developing specific complications and allow improved prognostic advice for patients and family members. We have evaluated Pyrosequencing technology for the detection and estimation of heteroplasmy for six mitochondrial point mutations associated with the following diseases: Leber's hereditary optical neuropathy (LHON), G3460A, G11778A, and T14484C; mitochondrial encephalopathy with lactic acidosis and stroke-like episodes (MELAS), A3243G; myoclonus epilepsy with ragged red fibers (MERRF), A8344G, and neurogenic muscle weakness, ataxia, and retinitis pigmentosa (NARP)/Leighs: T8993G/C. Results obtained from the Pyrosequencing assays for 50 patients with presumptive mitochondrial disease were compared to those obtained using the commonly used diagnostic technique of polymerase chain reaction (PCR) and restriction enzyme digestion. The Pyrosequencing assays provided accurate genotyping and quantitative determination of mutational load with a sensitivity and specificity of 100%. The MELAS A3243G mutation was detected reliably at a level of 1% heteroplasmy. We conclude that Pyrosequencing is a rapid and robust method for detecting heteroplasmic mitochondrial point mutations.
This record has no associated files available for download.
More information
Published date: 2005
Identifiers
Local EPrints ID: 25037
URI: http://eprints.soton.ac.uk/id/eprint/25037
ISSN: 1090-6576
PURE UUID: e25cd27a-da00-4d52-b0ac-4a49183a7984
Catalogue record
Date deposited: 04 Apr 2006
Last modified: 16 Mar 2024 03:23
Export record
Altmetrics
Contributors
Author:
Helen E. White
Author:
Victoria J. Durston
Author:
Anneke Seller
Author:
Carl Fratter
Author:
John F. Harvey
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics